Skip to main content
Erschienen in: Annals of Behavioral Medicine 6/2017

21.04.2017 | Original Article

A Randomized Controlled Trial of Rise, a Community-Based Culturally Congruent Adherence Intervention for Black Americans Living with HIV

verfasst von: Laura M. Bogart, PhD, Matt G. Mutchler, PhD, Bryce McDavitt, PhD, David J. Klein, MS, William E. Cunningham, MD, Kathy J. Goggin, PhD, Bonnie Ghosh-Dastidar, PhD, Nikki Rachal, BA, Kelsey A. Nogg, BA, Glenn J. Wagner, PhD

Erschienen in: Annals of Behavioral Medicine | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Evidence-based HIV treatment adherence interventions have typically shown medium-sized effects on adherence. Prior evidence-based HIV treatment adherence interventions have not been culturally adapted specifically for Black/African Americans, the population most affected by HIV disparities in the USA, who exhibit lower adherence than do members of other racial/ethnic groups.

Purpose

We conducted a randomized controlled trial of Rise, a 6-month culturally congruent adherence counseling intervention for HIV-positive Black men and women.

Methods

Rise was delivered by a trained peer counselor who used a problem-solving approach to address culturally congruent adherence barriers (e.g., medical mistrust, HIV stigma) and assisted with linkage to supportive services. A total of 215 participants were randomized to the intervention group (n = 107) or a wait-list control group (n = 108). Adherence was assessed daily via electronic monitoring.

Results

In a repeated measures multivariate logistic regression model of dichotomous adherence (using a clinically significant cutoff of 85% of doses taken), adjusted for sociodemographic and medical covariates, adherence in the intervention group improved over time relative to the control group, (OR = 1.30 per month (95% CI = 1.12–1.51), p < 0.001), representing a large cumulative effect after 6 months (OR = 4.76, Cohen’s d = 0.86).

Conclusions

Rise showed a larger effect on adherence than prior HIV adherence intervention studies. For greater effectiveness, interventions to improve adherence among Black people living with HIV may need to be customized to address culturally relevant barriers to adherence. (ClinicalTrials.​gov #NCT01350544)
Literatur
1.
Zurück zum Zitat Centers for Disease Control and Prevention. HIV in the United States: The Stages of Care. Atlanta. Department of Health and Human Services;2012. Centers for Disease Control and Prevention. HIV in the United States: The Stages of Care. Atlanta. Department of Health and Human Services;2012.
2.
Zurück zum Zitat Simoni JM, Huh D, Wilson IB, et al. Racial/ethnic disparities in ART adherence in the United States: Findings from the MACH14 study. J Acquir Immune Defic Syndr. 2012;60(5):466–472. Simoni JM, Huh D, Wilson IB, et al. Racial/ethnic disparities in ART adherence in the United States: Findings from the MACH14 study. J Acquir Immune Defic Syndr. 2012;60(5):466–472.
4.
Zurück zum Zitat Earnshaw V, Bogart LM, Dovidio J, Williams D Stigma and racial/ethnic HIV disparities: Moving towards resilience. Am Psychol. 2013;68(4):225–236.CrossRefPubMedPubMedCentral Earnshaw V, Bogart LM, Dovidio J, Williams D Stigma and racial/ethnic HIV disparities: Moving towards resilience. Am Psychol. 2013;68(4):225–236.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Bogart LM, Wagner GJ, Green HD, Mutchler MG, Klein DJ, McDavitt B. Social network characteristics moderate the association between stigmatizing attributions about HIV and non-adherence among black Americans living with HIV: A longitudinal assessment. Ann Behav Med. 2015;49(6):865–872.CrossRefPubMedPubMedCentral Bogart LM, Wagner GJ, Green HD, Mutchler MG, Klein DJ, McDavitt B. Social network characteristics moderate the association between stigmatizing attributions about HIV and non-adherence among black Americans living with HIV: A longitudinal assessment. Ann Behav Med. 2015;49(6):865–872.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bogart LM, Wagner GJ, Green HD et al., Medical mistrust among social network members may contribute to antiretroviral treatment nonadherence in African Americans living with HIV. Soc Sci Med. 2016;164:133–140.CrossRefPubMedPubMedCentral Bogart LM, Wagner GJ, Green HD et al., Medical mistrust among social network members may contribute to antiretroviral treatment nonadherence in African Americans living with HIV. Soc Sci Med. 2016;164:133–140.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Bogart LM, Wagner GJ, Galvan FH, Klein DJ. Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV-serostatus, race, and sexual orientation among African American men with HIV. Ann Behav Med. 2010;40(2):184–190.CrossRefPubMedPubMedCentral Bogart LM, Wagner GJ, Galvan FH, Klein DJ. Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV-serostatus, race, and sexual orientation among African American men with HIV. Ann Behav Med. 2010;40(2):184–190.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African American men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648–655.PubMedPubMedCentral Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African American men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648–655.PubMedPubMedCentral
9.
Zurück zum Zitat Rumptz MH, Tobias C, Rajabiun S, et al. Factors associated with engaging socially marginalized HIV-positive persons in primary care. AIDS Patient Care STDS. 2007;21(suppl 1):S30-S39.PubMed Rumptz MH, Tobias C, Rajabiun S, et al. Factors associated with engaging socially marginalized HIV-positive persons in primary care. AIDS Patient Care STDS. 2007;21(suppl 1):S30-S39.PubMed
10.
Zurück zum Zitat Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with Human Immunodeficiency Virus receiving care in the United States. Med Care. 1999;37(12):1270–1281. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with Human Immunodeficiency Virus receiving care in the United States. Med Care. 1999;37(12):1270–1281.
11.
Zurück zum Zitat Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Barnighausen T. Interventions to improve adherence to antiretroviral therapy: A rapid systematic review. AIDS. 2014;28(Suppl 2):S187–204.CrossRefPubMed Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Barnighausen T. Interventions to improve adherence to antiretroviral therapy: A rapid systematic review. AIDS. 2014;28(Suppl 2):S187–204.CrossRefPubMed
12.
Zurück zum Zitat Mathes T, Pieper D, Antoine SL, Eikermann M. Adherence-enhancing interventions for highly active antiretroviral therapy in HIV-infected patients—A systematic review. HIV Medicine. 2013;14(10):583–595.CrossRefPubMed Mathes T, Pieper D, Antoine SL, Eikermann M. Adherence-enhancing interventions for highly active antiretroviral therapy in HIV-infected patients—A systematic review. HIV Medicine. 2013;14(10):583–595.CrossRefPubMed
13.
Zurück zum Zitat Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: Translating research findings to the real world clinic. Current HIV/AIDS Reports. 2010;7(1):44–51.CrossRefPubMedPubMedCentral Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: Translating research findings to the real world clinic. Current HIV/AIDS Reports. 2010;7(1):44–51.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: A research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285–297.CrossRefPubMed Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: A research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285–297.CrossRefPubMed
15.
Zurück zum Zitat Charania MR, Marshall KJ, Lyles CM, et al. Identification of evidence-based interventions for promoting HIV medication adherence: Findings from a systematic review of U.S.-based studies, 1996-2011. AIDS Behav. 2014;18(4):646–660.CrossRefPubMedPubMedCentral Charania MR, Marshall KJ, Lyles CM, et al. Identification of evidence-based interventions for promoting HIV medication adherence: Findings from a systematic review of U.S.-based studies, 1996-2011. AIDS Behav. 2014;18(4):646–660.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wagner GJ, Bogart LM, Mutchler MG, McDavitt B, Mutepfa KD, Risley B. Increasing antiretroviral adherence for HIV-positive African Americans (project Rise): A treatment education intervention protocol. JMIR Res Protoc. 2016;5(1):e45.CrossRefPubMedPubMedCentral Wagner GJ, Bogart LM, Mutchler MG, McDavitt B, Mutepfa KD, Risley B. Increasing antiretroviral adherence for HIV-positive African Americans (project Rise): A treatment education intervention protocol. JMIR Res Protoc. 2016;5(1):e45.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Bogart LM, Wagner GJ, Mutchler MG, et al. Community HIV treatment advocacy programs may support treatment adherence. AIDS Educ Prev. 2012;24(1):1–14.CrossRefPubMedPubMedCentral Bogart LM, Wagner GJ, Mutchler MG, et al. Community HIV treatment advocacy programs may support treatment adherence. AIDS Educ Prev. 2012;24(1):1–14.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Mutchler MG, Wagner G, Cowgill BO, McKay T, Risley B, Bogart LM. Improving HIV/AIDS care through treatment advocacy: Going beyond client education to empowerment by facilitating client–provider relationships. AIDS Care. 2011;23(1):79–90.CrossRefPubMedPubMedCentral Mutchler MG, Wagner G, Cowgill BO, McKay T, Risley B, Bogart LM. Improving HIV/AIDS care through treatment advocacy: Going beyond client education to empowerment by facilitating client–provider relationships. AIDS Care. 2011;23(1):79–90.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepatz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(suppl 1):S23-S35.CrossRefPubMedPubMedCentral Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepatz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(suppl 1):S23-S35.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat U.S. Department of Health and Human Services. Redefining Case Management. Rockville, MD; 2008. U.S. Department of Health and Human Services. Redefining Case Management. Rockville, MD; 2008.
22.
Zurück zum Zitat Kaufman MR, Cornish F, Zimmerman RS, Johnson BT. Health behavior change models for HIV prevention and AIDS care: Practical recommendations for a multi-level approach. J Acquir Immune Defic Syndr. 2014;66(Suppl 3):S250-S258.CrossRefPubMed Kaufman MR, Cornish F, Zimmerman RS, Johnson BT. Health behavior change models for HIV prevention and AIDS care: Practical recommendations for a multi-level approach. J Acquir Immune Defic Syndr. 2014;66(Suppl 3):S250-S258.CrossRefPubMed
23.
Zurück zum Zitat Starace F, Massa A, Amico KR, Fisher JD. Adherence to antiretroviral therapy: An empirical test of the information-motivation-behavioral skills model. Health Psychol. 2006;25(2):153–162.CrossRefPubMed Starace F, Massa A, Amico KR, Fisher JD. Adherence to antiretroviral therapy: An empirical test of the information-motivation-behavioral skills model. Health Psychol. 2006;25(2):153–162.CrossRefPubMed
24.
Zurück zum Zitat Smith R, Rossetto K, Peterson BL. A meta-analysis of disclosure of one's HIV-positive status, stigma and social support. AIDS Care. 2008;20(10):1266–1275.CrossRefPubMed Smith R, Rossetto K, Peterson BL. A meta-analysis of disclosure of one's HIV-positive status, stigma and social support. AIDS Care. 2008;20(10):1266–1275.CrossRefPubMed
25.
Zurück zum Zitat Katz MH, Cunningham WE, Fleishman JA, et al. Effects of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Ann Intern Med. 2001;135(8):557–565.CrossRefPubMed Katz MH, Cunningham WE, Fleishman JA, et al. Effects of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Ann Intern Med. 2001;135(8):557–565.CrossRefPubMed
26.
Zurück zum Zitat Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423–431.CrossRefPubMed Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423–431.CrossRefPubMed
27.
Zurück zum Zitat Williams JK, Wyatt GE, Wingood G. The four C's of HIV prevention with African Americans: Crisis, condoms, culture, and community. Curr HIV/AIDS Rep. 2010;7(4):185–193.CrossRefPubMedPubMedCentral Williams JK, Wyatt GE, Wingood G. The four C's of HIV prevention with African Americans: Crisis, condoms, culture, and community. Curr HIV/AIDS Rep. 2010;7(4):185–193.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Wyatt GE. Enhancing cultural and contextual intervention strategies to reduce HIV/AIDS among African Americans. Am J Public Health. 2009;99(11):1941–1945.CrossRefPubMedPubMedCentral Wyatt GE. Enhancing cultural and contextual intervention strategies to reduce HIV/AIDS among African Americans. Am J Public Health. 2009;99(11):1941–1945.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: Does it help explain gender disparities in HAART use? J Womens Health (Larchmt). 2006;15(2):173–181.CrossRef Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: Does it help explain gender disparities in HAART use? J Womens Health (Larchmt). 2006;15(2):173–181.CrossRef
30.
Zurück zum Zitat Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. 3rd ed. New York, NY: Guilford Press; 2013. Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. 3rd ed. New York, NY: Guilford Press; 2013.
31.
Zurück zum Zitat Division of HIV and STD Programs Los Angeles County Department of Public Health. 2014 Annual HIV/STD Surveillance Report; 2016. Division of HIV and STD Programs Los Angeles County Department of Public Health. 2014 Annual HIV/STD Surveillance Report; 2016.
32.
Zurück zum Zitat Moyers T, Martin T, Manuel J, Miller WR. The motivational interviewing treatment integrity (MITI) code, version 2.0. New Mexico: University of New Mexico, Center on Alcoholism, Substance Abuse and Addictions; Unpublished. Moyers T, Martin T, Manuel J, Miller WR. The motivational interviewing treatment integrity (MITI) code, version 2.0. New Mexico: University of New Mexico, Center on Alcoholism, Substance Abuse and Addictions; Unpublished.
33.
Zurück zum Zitat Simoni JM, Kurth AE, Pearso CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for research and clinical management. AIDS Behav. 2006;10(3):227–245.CrossRefPubMedPubMedCentral Simoni JM, Kurth AE, Pearso CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for research and clinical management. AIDS Behav. 2006;10(3):227–245.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–381.CrossRefPubMedPubMedCentral Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–381.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–366.CrossRefPubMed Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–366.CrossRefPubMed
36.
Zurück zum Zitat Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–941.CrossRefPubMed Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–941.CrossRefPubMed
37.
Zurück zum Zitat Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–379.CrossRefPubMed Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–379.CrossRefPubMed
38.
Zurück zum Zitat Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving Lopinavir/Ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45(1):4–8.CrossRefPubMed Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving Lopinavir/Ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45(1):4–8.CrossRefPubMed
39.
Zurück zum Zitat Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–322.CrossRefPubMed Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–322.CrossRefPubMed
40.
Zurück zum Zitat Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender disparities in HIV treatment outcomes following release from jail: Results from a multicenter study. Am J Public Health. 2014;104(3):434–441.CrossRefPubMedPubMedCentral Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender disparities in HIV treatment outcomes following release from jail: Results from a multicenter study. Am J Public Health. 2014;104(3):434–441.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19(22):3127–3131.CrossRefPubMed Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19(22):3127–3131.CrossRefPubMed
42.
Zurück zum Zitat Wilson IB, Bangsberg DR, Shen J, et al. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: Results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr. 2013;64(5):448–454.CrossRefPubMedPubMedCentral Wilson IB, Bangsberg DR, Shen J, et al. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: Results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr. 2013;64(5):448–454.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Remien RH, Stirratt MJ, Dolezal C, et al. Couple-focused support to improve HIV medication adherence: A randomized controlled trial. AIDS. 2005;19(8):807–814.CrossRefPubMed Remien RH, Stirratt MJ, Dolezal C, et al. Couple-focused support to improve HIV medication adherence: A randomized controlled trial. AIDS. 2005;19(8):807–814.CrossRefPubMed
44.
Zurück zum Zitat Wagner GJ, Rabkin JG. Measuring medication adherence: Are missed doses reported more accurately than perfect adherence? AIDS Care. 2000;12(4):405–408.CrossRefPubMed Wagner GJ, Rabkin JG. Measuring medication adherence: Are missed doses reported more accurately than perfect adherence? AIDS Care. 2000;12(4):405–408.CrossRefPubMed
45.
Zurück zum Zitat Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–1423.CrossRefPubMedPubMedCentral Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–1423.CrossRefPubMedPubMedCentral
Metadaten
Titel
A Randomized Controlled Trial of Rise, a Community-Based Culturally Congruent Adherence Intervention for Black Americans Living with HIV
verfasst von
Laura M. Bogart, PhD
Matt G. Mutchler, PhD
Bryce McDavitt, PhD
David J. Klein, MS
William E. Cunningham, MD
Kathy J. Goggin, PhD
Bonnie Ghosh-Dastidar, PhD
Nikki Rachal, BA
Kelsey A. Nogg, BA
Glenn J. Wagner, PhD
Publikationsdatum
21.04.2017
Verlag
Springer US
Erschienen in
Annals of Behavioral Medicine / Ausgabe 6/2017
Print ISSN: 0883-6612
Elektronische ISSN: 1532-4796
DOI
https://doi.org/10.1007/s12160-017-9910-4

Weitere Artikel der Ausgabe 6/2017

Annals of Behavioral Medicine 6/2017 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.